This module uses fundamental data of China SXT to approximate its Piotroski F score. China SXT F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of China SXT Pharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about China SXT financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out China SXT Altman Z Score, China SXT Correlation, China SXT Valuation, as well as analyze China SXT Alpha and Beta and China SXT Hype Analysis.
China
Piotroski F Score
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Net Borrowings
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Investments
Stock Based Compensation
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Net Receivables
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Intangible Assets
Common Stock
Property Plant Equipment
Short Long Term Debt Total
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Non Current Assets Total
Non Currrent Assets Other
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Property Plant And Equipment Gross
Short Long Term Debt
Accumulated Other Comprehensive Income
Other Assets
Net Invested Capital
Net Working Capital
Capital Stock
Long Term Debt
Tax Provision
Interest Income
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Operating Income
Net Income From Continuing Ops
Ebit
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Depreciation And Amortization
Selling And Marketing Expenses
Other Operating Expenses
Ebitda
Reconciled Depreciation
Probability Of Bankruptcy
At present, China SXT's Debt To Equity is projected to slightly decrease based on the last few years of reporting. The current year's Long Term Debt To Capitalization is expected to grow to 0.01, whereas Short Term Debt is forecasted to decline to about 1.9 M. At present, China SXT's Inventory Turnover is projected to increase slightly based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 1.43, whereas Price To Sales Ratio is forecasted to decline to 0.71.
At this time, it appears that China SXT's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to China SXT is to make sure China is not a subject of accounting manipulations and runs a healthy internal audit department. So, if China SXT's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if China SXT's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between China SXT's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards China SXT in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
15.26
At present, China SXT's Book Value Per Share is projected to decrease significantly based on the last few years of reporting.
About China SXT Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze China SXT Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China SXT using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China SXT Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.426
Earnings Share
(3.57)
Revenue Per Share
2.223
Quarterly Revenue Growth
0.295
Return On Assets
(0.05)
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.